S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Better Than Oil Stocks? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$34.73
-0.54 (-1.53%)
(As of 09/29/2023 ET)
Compare
Today's Range
$33.53
$36.19
50-Day Range
$29.80
$37.76
52-Week Range
$23.89
$47.25
Volume
482,713 shs
Average Volume
537,853 shs
Market Capitalization
$2.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.88

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.6% Upside
$57.88 Price Target
Short Interest
Bearish
21.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.01mentions of Ventyx Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$17.78 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.26) to ($3.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

826th out of 970 stocks

Pharmaceutical Preparations Industry

389th out of 451 stocks


VTYX stock logo

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

VTYX Price History

VTYX Stock News Headlines

Ventyx Biosciences (NASDAQ:VTYX) Stock Price Down 2.5%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
Ventyx Biosciences (NASDAQ: VTYX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Where Ventyx Biosciences Stands With Analysts
Analyst Ratings for Ventyx Biosciences
LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)
Why Shares of Ventyx Biosciences Rose Monday
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.88
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+66.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-108,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.25 per share

Miscellaneous

Free Float
44,391,000
Market Cap
$2.04 billion
Optionable
Not Optionable
Beta
-0.36
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 53)
    Exec. Chairperson
    Comp: $125k
  • Dr. Raju S. Mohan Ph.D. (Age 65)
    Founder, CEO & Director
    Comp: $989.99k
  • Dr. William J. Sandborn M.D. (Age 60)
    Ph.D., Pres & Chief Medical Officer
    Comp: $872.26k
  • Dr. John M. Nuss Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $656.99k
  • Dr. Martin Douglas Auster M.D. (Age 48)
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D. (Age 55)
    MBA, Chief Bus. Officer













VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month target prices for Ventyx Biosciences' stock. Their VTYX share price forecasts range from $46.00 to $77.00. On average, they expect the company's stock price to reach $57.88 in the next twelve months. This suggests a possible upside of 66.6% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2023?

Ventyx Biosciences' stock was trading at $32.79 at the beginning of 2023. Since then, VTYX stock has increased by 5.9% and is now trading at $34.73.
View the best growth stocks for 2023 here
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.20. During the same quarter in the prior year, the firm earned ($0.39) earnings per share.

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $34.73.

How much money does Ventyx Biosciences make?

Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $2.04 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How can I contact Ventyx Biosciences?

The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -